The warning signs are getting harder to ignore. What began as a safety signal in medical journals is now spilling into courtrooms, regulatory reviews, and urgent conversations in doctors’ offices.
Why the “5 times higher” headline is getting attention
The claim that Wegovy users are going blind at 5 times the rate of Ozempic users comes from a newer 2026 analysis published in the British Journal of Ophthalmology, which examined millions of adverse-event reports in the FDA’s reporting system. Researchers found that Wegovy carried a markedly stronger reporting signal for ischemic optic neuropathy than Ozempic, with an adjusted odds ratio of about 4.74. That does not mean 5 out of every 1 patient will lose vision, or even that the drug has been proven to cause the condition, but it does explain why the headline has spread so quickly.
The eye disorder at the center of the alarm is non-arteritic anterior ischemic optic neuropathy, or NAION. It is sometimes described as an “eye stroke” because it involves reduced blood flow to the optic nerve and can lead to sudden, sometimes permanent, vision loss, usually in one eye. According to the European Medicines Agency and the UK’s medicines regulator, semaglutide medicines including Wegovy and Ozempic have been linked to NAION as a very rare side effect, even as regulators stress that the absolute risk remains low.
The newer British Journal of Ophthalmology study did not emerge in a vacuum. In 2024, a JAMA Ophthalmology study from Mass Eye and Ear and Harvard researchers reported that patients with type 2 diabetes prescribed semaglutide were more than four times as likely to receive a NAION diagnosis as matched patients taking other diabetes drugs. In the overweight or obesity group, the relative risk signal was even stronger compared with patients taking non-GLP-1 weight-loss medications. That early study helped move the issue from anecdote to something ophthalmologists, endocrinologists, and safety regulators could no longer dismiss.
Still, relative risk can sound far more dramatic than absolute risk. Experts quoted in follow-up coverage have repeatedly emphasized that NAION remains uncommon, even among semaglutide users. The real significance of the newer finding is not that Wegovy users should assume blindness is likely, but that two formulations with the same active ingredient now appear to show different risk signals, raising questions about dose, patient selection, speed of weight loss, and whether obesity-treatment populations may face a distinct pattern of vulnerability.
What the science actually shows about Wegovy, Ozempic, and vision loss
The strongest evidence so far remains observational, not proof of causation. The 2024 JAMA Ophthalmology paper looked at 16,827 patients seen at a major neuro-ophthalmology referral center and found a higher cumulative incidence of NAION among semaglutide users than among comparable patients on other therapies. More recently, a 2025 multicenter JAMA Ophthalmology study using 14 databases across the OHDSI research network, representing 37.1 million adults with type 2 diabetes, found a small relative increase in the incidence of NAION associated with semaglutide exposure. That broadened the safety discussion beyond a single elite specialty center.
The 2026 British Journal of Ophthalmology analysis added a different layer by examining FDA adverse-event reports from 2017 through 2024. In that dataset, Wegovy stood out more strongly than Ozempic, and men appeared to have a higher signal than women. Researchers and outside commentators have suggested one plausible explanation: Wegovy is typically used at higher semaglutide doses than Ozempic, which may point to a dose-related effect. That idea remains a hypothesis, but it is one reason the formulation-specific result is drawing so much interest.
At the same time, there are important caveats. Spontaneous reporting databases like FAERS are useful for spotting safety signals, but they are vulnerable to underreporting, duplicate reports, publicity effects, and confounding. They cannot by themselves show how often an event truly occurs in the real world, nor can they fully separate drug effects from patient characteristics such as diabetes, hypertension, sleep apnea, or vascular disease, all of which may influence NAION risk on their own.
That nuance matters because semaglutide users are not a uniform group. Ozempic is primarily prescribed for type 2 diabetes, while Wegovy is prescribed for obesity and, in some patients, cardiovascular risk reduction. The diseases being treated, the doses used, and the baseline vascular risks may differ in ways that complicate direct comparison. Even so, regulators in Europe and the UK have already moved further than US labeling on this issue, concluding that NAION should be recognized as a very rare semaglutide-associated risk. The science is not settled, but it is no longer speculative enough to ignore.
Why lawsuits are being filed now
Litigation tends to follow a familiar path in drug safety controversies. First comes an emerging cluster of patient reports, then a study or two that gives the claims scientific scaffolding, then plaintiff lawyers begin testing whether manufacturers adequately warned patients and physicians. That sequence is now visible in semaglutide blindness cases, with lawsuits alleging that drugs such as Wegovy and Ozempic triggered NAION and that the risk was not sufficiently disclosed.
Reuters has reported that blindness-related GLP-1 lawsuits have developed into a second major wave of product-liability litigation over this drug class, separate from the better-known gastroparesis and gastrointestinal injury claims. Court filings and legal industry tracking show that cases have been brought by patients who say they suffered sudden vision loss after taking semaglutide medicines. Some complaints argue that the manufacturers knew or should have known of the risk earlier, especially as case reports and signal analyses accumulated.
The legal argument will likely turn on timing as much as science. Drug makers are not expected to warn about every theoretical hazard, but they can face scrutiny if plaintiffs persuade courts that a meaningful signal existed before labeling or safety communications caught up. In Europe, regulators have already described NAION as a very rare side effect of semaglutide medicines. In the UK, updated product information now tells patients to seek urgent medical attention for sudden vision loss or rapidly worsening eyesight. In the US, however, current official prescribing information for Wegovy and Ozempic still prominently discusses diabetic retinopathy complications but does not clearly list NAION as a labeled warning.
That gap between evolving evidence and label language is exactly the kind of territory where lawsuits multiply. Plaintiffs’ lawyers will likely present the 2024 and 2025 academic studies, the 2026 adverse-event analysis, and European regulatory action as signs that the risk was real and actionable. Defense lawyers, in turn, will emphasize that NAION is rare, that the evidence remains observational, and that patients receiving semaglutide often already carry vascular and metabolic risk factors associated with eye disease.
For now, the courtroom story is still in its early innings. That means there has been no definitive judicial finding that Wegovy causes blindness or that any company acted unlawfully. But the filing wave matters because it often forces internal safety documents, expert testimony, and regulatory chronology into public view, which can reshape the public understanding of risk long before any verdict is reached.
What patients should know before panic takes over
For most patients, the most important message is not to stop medication abruptly out of fear. Semaglutide drugs can produce substantial benefits, including weight loss, blood sugar improvement, and in some populations lower cardiovascular risk. Experts commenting on the latest eye-risk studies have stressed that the overall risk of NAION appears to be extremely low, and untreated obesity or diabetes can themselves damage vision, cardiovascular health, kidney function, and long-term survival.
That said, sudden vision symptoms should be treated as a medical emergency. UK regulators now advise semaglutide patients to seek urgent evaluation if they experience sudden loss of vision or rapidly worsening eyesight. NAION typically affects one eye at a time and can appear suddenly, often upon waking. Other symptoms may include a shadow or dim area in the visual field, reduced sharpness, or changes in color perception. Because time matters, patients should not wait for a routine appointment if these symptoms appear.
Patients should also understand that not all vision problems on these drugs are the same. Ozempic and Wegovy labeling already warns about diabetic retinopathy complications in some patients with type 2 diabetes, which is distinct from NAION. Retinopathy involves damage to blood vessels in the retina and can worsen during periods of rapid glucose improvement. NAION, by contrast, involves the optic nerve. Lumping every eye complaint into one category can blur the actual medical issue and make informed decisions harder.
A better approach is targeted discussion with a prescribing clinician. Patients with prior optic nerve disease, severe vascular risk factors, sleep apnea, longstanding diabetes, or a previous NAION event in the other eye may want a more individualized risk-benefit review. Men may also ask about the sex-specific signal reported in the 2026 analysis, though that finding still needs confirmation. The central question is not whether Wegovy is “safe” in some absolute sense, but whether its benefits outweigh a very rare, potentially severe risk for a specific person.
Where this story is likely headed next
The next phase will be driven by three forces: better epidemiology, regulatory action, and litigation discovery. Researchers will need larger real-world comparative studies that can better control for diabetes severity, obesity, blood pressure, sleep apnea, smoking, and other vascular confounders. The existing literature suggests a possible association and maybe even a dose effect, but doctors still need a clearer estimate of absolute risk and a better understanding of which patients are most vulnerable.
Regulators are also unlikely to leave the issue where it is. The European Medicines Agency has already said NAION should be regarded as a very rare side effect of semaglutide medicines, citing large epidemiologic studies that suggest about a twofold increase in risk among adults with type 2 diabetes taking semaglutide compared with non-users. The UK followed with updated safety language in February 2026. If additional studies continue to point in the same direction, pressure will grow for US labeling and safety communications to evolve as well.
Manufacturers, meanwhile, face a reputational as well as legal challenge. Novo Nordisk has said patient safety is its top priority and has cautioned that current evidence does not establish a causal relationship. That is a standard and, at this stage, defensible position. But blockbuster drugs live under a harsher spotlight than ordinary medicines, especially when prescribed so broadly and discussed so publicly. Even rare harms can become major public issues when exposure numbers are enormous.
The most responsible takeaway is neither denial nor alarmism. The “5 times” figure is newsworthy because it suggests Wegovy may carry a meaningfully stronger vision-loss signal than Ozempic despite sharing semaglutide as the active ingredient. But the broader medical reality is more complicated: the condition is rare, the evidence is still evolving, and the benefits of these drugs remain substantial for many patients. What has changed is that NAION is no longer a fringe concern. It is now a recognized safety issue under active scientific, regulatory, and legal examination.